Trials / Completed
CompletedNCT01088711
Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK3102 in Obese Subjects and in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 45 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study will test the safety and tolerability of omarigliptin. It is hypothesized that administration of once-weekly omarigliptin in obese but otherwise healthy participants, and in obese participants with Type 2 diabetes (T2D) will be sufficiently safe and well tolerated to permit continued clinical investigation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omarigliptin | Once-weekly 50 mg capsule |
| DRUG | Placebo | Once-weekly placebo capsule |
Timeline
- Start date
- 2010-03-11
- Primary completion
- 2010-05-11
- Completion
- 2010-05-11
- First posted
- 2010-03-17
- Last updated
- 2018-09-10
- Results posted
- 2015-12-24
Source: ClinicalTrials.gov record NCT01088711. Inclusion in this directory is not an endorsement.